Indications

• Respiratory Syncytial Virus (RSV) (see Respiratory Syncytial Virus, [[Respiratory Syncytial Virus]])
  • No clinical benefit in established RSV infection
  • Licensed for the prevention of serious RSV lower respiratory tract disease in children at high risk of RSV infection (prematurity, bronchopulmonary dysplasia, congenital heart disease)

---

Pharmacology

• Respiratory Syncytial Virus-Specific Humanized Monoclonal Antibody

---

Administration

• xxxx

Dose Adjustment

• Hepatic:
• Renal:

---

Adverse Effects

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• xxxx